BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gattone VH 2nd, Sinders RM, Hornberger TA, Robling AG. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 2009;76:178-82. [PMID: 19421190 DOI: 10.1038/ki.2009.147] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiao T, Guan X, Nie L, Wang S, Sun L, He T, Huang Y, Zhang J, Yang K, Wang J, Zhao J. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice. Mol Cell Biochem 2014;394:145-54. [DOI: 10.1007/s11010-014-2090-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
2 Stokman MF, Saunier S, Benmerah A. Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis. Front Cell Dev Biol 2021;9:653138. [PMID: 34055783 DOI: 10.3389/fcell.2021.653138] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Irazabal MV, Torres VE. Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev 2013;9:44-59. [PMID: 23971644 DOI: 10.2174/1573402111309010008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Kurbegovic A, Trudel M. Acute kidney injury induces hallmarks of polycystic kidney disease. American Journal of Physiology-Renal Physiology 2016;311:F740-51. [DOI: 10.1152/ajprenal.00167.2016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
5 Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011;300:F465-74. [PMID: 21147840 DOI: 10.1152/ajprenal.00460.2010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
6 Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010;21:489-97. [PMID: 20075061 DOI: 10.1681/ASN.2009040421] [Cited by in Crossref: 171] [Cited by in F6Publishing: 102] [Article Influence: 14.3] [Reference Citation Analysis]
7 Margaria JP, Campa CC, De Santis MC, Hirsch E, Franco I. The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium. Cell Signal 2020;66:109468. [PMID: 31715259 DOI: 10.1016/j.cellsig.2019.109468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Anderson S, Oyama TT, Lindsley JN, Schutzer WE, Beard DR, Gattone VH 2nd, Komers R. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am J Physiol Renal Physiol 2012;302:F636-45. [PMID: 22160773 DOI: 10.1152/ajprenal.00265.2011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
9 Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. American Journal of Physiology-Renal Physiology 2009;297:F1597-605. [DOI: 10.1152/ajprenal.00430.2009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
10 Gupta S, Ozimek-Kulik JE, Phillips JK. Nephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease. Genes (Basel) 2021;12:1762. [PMID: 34828368 DOI: 10.3390/genes12111762] [Reference Citation Analysis]
11 Abdul-Majeed S, Nauli SM. Calcium-mediated mechanisms of cystic expansion. Biochim Biophys Acta 2011;1812:1281-90. [PMID: 20932898 DOI: 10.1016/j.bbadis.2010.09.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
12 Paces-fessy M. Cils et kystes rénaux. Med Sci (Paris) 2014;30:1024-33. [DOI: 10.1051/medsci/20143011017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Molinari E, Sayer JA. Emerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease. Expert Opinion on Orphan Drugs 2017;5:785-98. [DOI: 10.1080/21678707.2017.1372282] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
14 Wallace DP, White C, Savinkova L, Nivens E, Reif GA, Pinto CS, Raman A, Parnell SC, Conway SJ, Fields TA. Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease. Kidney Int 2014;85:845-54. [PMID: 24284511 DOI: 10.1038/ki.2013.488] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
15 Sugimoto K, Miyazawa T, Enya T, Nishi H, Miyazaki K, Okada M, Takemura T. Clinical and genetic characteristics of Japanese nephronophthisis patients. Clin Exp Nephrol. 2016;20:637-649. [PMID: 26499951 DOI: 10.1007/s10157-015-1180-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, Shen X, Hua Z. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 2010;119:323-33. [PMID: 20507283 DOI: 10.1042/CS20100113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
17 Millet-Boureima C, Porras Marroquin J, Gamberi C. Modeling Renal Disease "On the Fly". Biomed Res Int 2018;2018:5697436. [PMID: 29955604 DOI: 10.1155/2018/5697436] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
18 Wüthrich R, Kistler A, Serra A. Impact of Mammalian Target of Rapamycin Inhibition on Autosomal-Dominant Polycystic Kidney Disease. Transplantation Proceedings 2010;42:S44-6. [DOI: 10.1016/j.transproceed.2010.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
19 Gamberi C, Hipfner DR, Trudel M, Lubell WD. Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila. PLoS Genet 2017;13:e1006694. [PMID: 28406902 DOI: 10.1371/journal.pgen.1006694] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kelly KJ, Zhang J, Han L, Kamocka M, Miller C, Gattone VH 2nd, Dominguez JH. Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy. PLoS One 2015;10:e0131677. [PMID: 26136112 DOI: 10.1371/journal.pone.0131677] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29. [PMID: 20498248 DOI: 10.2215/CJN.01360210] [Cited by in Crossref: 75] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
22 Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Am J Physiol Renal Physiol. 2014;306:F1243-F1250. [PMID: 24647711 DOI: 10.1152/ajprenal.00694.2013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
23 Zhang JQJ, Burgess J, Stepanova D, Saravanabavan S, Wong ATY, Kaldis P, Rangan GK. Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease. Lab Invest 2020;100:696-711. [PMID: 31915367 DOI: 10.1038/s41374-019-0360-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Ta MH, Schwensen KG, Foster S, Korgaonkar M, Ozimek-Kulik JE, Phillips JK, Peduto A, Rangan GK. Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease. PLoS One 2016;11:e0164193. [PMID: 27723777 DOI: 10.1371/journal.pone.0164193] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gewin LS, Summers ME, Harral JW, Gaskill CF, Khodo SN, Neelisetty S, Sullivan TM, Hopp K, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM. Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney. Am J Physiol Renal Physiol 2019;317:F1201-10. [PMID: 31461347 DOI: 10.1152/ajprenal.00629.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124:2315-2324. [PMID: 24892705 DOI: 10.1172/jci72272] [Cited by in Crossref: 180] [Cited by in F6Publishing: 117] [Article Influence: 22.5] [Reference Citation Analysis]
27 Wiegering A, Rüther U, Gerhardt C. The Role of Primary Cilia in the Crosstalk between the Ubiquitin⁻Proteasome System and Autophagy. Cells 2019;8:E241. [PMID: 30875746 DOI: 10.3390/cells8030241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Raman A, Reif GA, Dai Y, Khanna A, Li X, Astleford L, Parnell SC, Calvet JP, Wallace DP. Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease. J Am Soc Nephrol. 2017;28:2708-2719. [PMID: 28522687 DOI: 10.1681/asn.2016111235] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
29 Srivastava S, Molinari E, Raman S, Sayer JA. Many Genes-One Disease? Front Pediatr. 2017;5:287. [PMID: 29379777 DOI: 10.3389/fped.2017.00287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
30 Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med. 2011;17:625-633. [PMID: 21775207 DOI: 10.1016/j.molmed.2011.06.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
31 Mason SB, Liang Y, Sinders RM, Miller CA, Eggleston-Gulyas T, Crisler-Roberts R, Harris PC, Gattone VH. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD. Anat Rec (Hoboken). 2010;293:1279-1288. [PMID: 20665806 DOI: 10.1002/ar.21166] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
32 Rogers KA, Moreno SE, Smith LA, Husson H, Bukanov NO, Ledbetter SR, Budman Y, Lu Y, Wang B, Ibraghimov-Beskrovnaya O, Natoli TA. Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. Physiol Rep 2016;4:e12846. [PMID: 27356569 DOI: 10.14814/phy2.12846] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
33 Kou P, Wei S, Xiong F. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? Curr Med Chem 2019;26:2962-73. [PMID: 29600752 DOI: 10.2174/0929867325666180330094434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Slaats GG, Lilien MR, Giles RH. Nephronophthisis: should we target cysts or fibrosis? Pediatr Nephrol 2016;31:545-54. [PMID: 26219413 DOI: 10.1007/s00467-015-3162-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
35 Hakim S, Dyson JM, Feeney SJ, Davies EM, Sriratana A, Koenig MN, Plotnikova OV, Smyth IM, Ricardo SD, Hobbs RM, Mitchell CA. Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling. Hum Mol Genet 2016;25:2295-313. [PMID: 27056978 DOI: 10.1093/hmg/ddw097] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
36 Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 2012;303:F180-91. [PMID: 22496407 DOI: 10.1152/ajprenal.00015.2012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
37 Viana SD, Reis F, Alves R. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. Oxid Med Cell Longev 2018;2018:3693625. [PMID: 30510618 DOI: 10.1155/2018/3693625] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
38 Natoli TA, Husson H, Rogers KA, Smith LA, Wang B, Budman Y, Bukanov NO, Ledbetter SR, Klinger KW, Leonard JP, Ibraghimov-Beskrovnaya O. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum Mol Genet 2012;21:3397-407. [PMID: 22563011 DOI: 10.1093/hmg/dds172] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]